A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Zev A. Wainberg, MD (ucla)

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Zev A. Wainberg, MD (ucla)
Zev Wainberg, M.D., holds the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Incyte Corporation
- ID
- NCT06179160
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 466 study participants
- Last Updated